Natera's Signatera detects gastroesophageal cancer recurrence over seven months ahead of imaging in trial

• Natera will present 20 abstracts at the European Society for Medical Oncology congress in Madrid, Spain, October 23-26, 2026.
• In the phase III SAGITTARIUS colon cancer trial, Signatera results prompted treatment changes, predominantly toward less intensive therapy following negative results.
• The ICONIC gastroesophageal cancer trial linked molecular residual disease clearance during preoperative therapy to lower recurrence risk and favorable pathological response.
• Signatera Genome detected all evaluable recurrences during ICONIC surveillance, identifying recurrence earlier than standard imaging.
• A metastatic breast cancer analysis found sustained negative results among most exceptional responders, supporting potential Signatera-guided reductions in treatment intensity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610181810BIZWIRE_USPR_____20261018_BW851261) on October 18, 2026, and is solely responsible for the information contained therein.